CRMD (cormedix.com) Net earnings per share (EPS TTM)

cormedix.com (CRMD) - corporate logo

The annual net income per share trend demonstrates profit dynamics, where 0.66 records a new level. Growth is driven by a lack of direct competitors and strong pricing power. The integration of Defencath into US medical standards and patent protection are creating positive momentum. CorMedix Inc. is strengthening its status as a reliable lifesaver by developing highly effective anti-infective solutions for dialysis.

CRMD (CorMedix Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/16/2026

CorMedix Corp (CRMD) - metric breakdowns and financial figures

- current quotes and average value forecast:
- business market valuation indicators:
Fundamental company analysis:CRMD - CorMedix Therapeutics
Flagship merchandise of CorMedix Inc

To select high-quality assets, an investor must compare a business's real returns with its market value using fundamental metrics. Earnings per share (TTM) measures the final financial result over a rolling year distributed across the total share issuance, which allows for an assessment of CorMedix Inc. antimicrobial solution sales efficiency through changes in rolling earnings per share.